NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Iovance Biotherapeutics Inc (NASDAQ:IOVA) announced its quarterly earnings results on Monday, November, 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.39) by $0.01. View Iovance Biotherapeutics' Earnings History.

Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Iovance Biotherapeutics.

12 brokerages have issued twelve-month target prices for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $38.00. On average, they expect Iovance Biotherapeutics' share price to reach $31.73 in the next year. This suggests a possible upside of 27.5% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.

Media stories about IOVA stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iovance Biotherapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Iovance Biotherapeutics.

Iovance Biotherapeutics saw a decrease in short interest in January. As of January 15th, there was short interest totalling 14,830,000 shares, a decrease of 9.5% from the December 31st total of 16,390,000 shares. Based on an average daily volume of 1,270,000 shares, the days-to-cover ratio is currently 11.7 days. Currently, 12.8% of the shares of the stock are sold short. View Iovance Biotherapeutics' Current Options Chain.

Some companies that are related to Iovance Biotherapeutics include Neurocrine Biosciences (NBIX), Qiagen (QGEN), BIO-TECHNE (TECH), BioNTech (BNTX), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP) and Momenta Pharmaceuticals (MNTA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Heron Therapeutics (HRTX), Novavax (NVAX) and Bristol-Myers Squibb (BMY).

Iovance Biotherapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (7.46%), Perceptive Advisors LLC (7.46%), Farallon Capital Management LLC (4.95%), Franklin Resources Inc. (4.34%), State Street Corp (3.43%) and Bank of America Corp DE (2.52%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.

IOVA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Franklin Resources Inc., Broadfin Capital LLC, State Street Corp, Rafferty Asset Management LLC, Peregrine Capital Management LLC and Credit Suisse AG. View Insider Buying and Selling for Iovance Biotherapeutics.

IOVA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Fairmount Funds Management LLC, Artisan Partners Limited Partnership, Eagle Asset Management Inc., Rothschild & Co. Asset Management US Inc., Crawford Lake Capital Management LLC, Farallon Capital Management LLC and EcoR1 Capital LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOVA stock can currently be purchased for approximately $24.89.

Iovance Biotherapeutics has a market capitalization of $3.14 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics.

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]